Literature DB >> 14695217

Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity.

Kheem S Bisht1, C Matthew Bradbury, David Mattson, Aradhana Kaushal, Anastasia Sowers, Stephanie Markovina, Karen L Ortiz, Leah K Sieck, Jennifer S Isaacs, Martin W Brechbiel, James B Mitchell, Leonard M Neckers, David Gius.   

Abstract

Ansamycin antibiotics inhibit function of the heat shock protein (HSP) 90, causing selective degradation of several intracellular proteins regulating such processes as proliferation, cell cycle regulation, and prosurvival signaling cascades. HSP90 has been identified previously as a molecular target for anticancer agents, including ionizing radiation (IR). Therefore, we hypothesized that the ansamycin geldanamycin and its 17-allylamino-17-demethoxy analog (17-AAG), which inhibit HSP90, would enhance tumor cell susceptibility to the cytotoxicity of IR. Treatment of two human cervical carcinoma cell lines (HeLa and SiHa) with geldanamycin and 17-AAG resulted in cytotoxicity and, when combined with IR, enhanced the radiation response, each effect with a temporal range from 6 to 48 h after drug exposure. In addition, mouse in vivo models using 17-AAG at clinically achievable concentrations yielded results that paralleled the in vitro radiosensitization studies of both single and fractioned courses of irradiation. The increase in IR-induced cell death appears to be attributable to a combination of both programmed and nonprogrammed cell death. We also measured total levels of several prosurvival and apoptotic signaling proteins. Akt1, extracellular signal-regulated kinase-1, Glut-1, HER-2/neu, Lyn, cAMP-dependent protein kinase, Raf-1, and vascular endothelial growth factor expression were down-regulated in 17-AAG-treated cells, identifying these factors as molecular markers and potential therapeutic targets. Finally, a series of immortalized and human papillomavirus-transformed cell lines were used to demonstrate that the radiosensitizing effects of 17-AAG were limited to transformed cells, suggesting a possible differential cytotoxic effect. This work shows that altered HSP90 function induces significant tumor cytotoxicity and radiosensitization, suggesting a potential therapeutic utility.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14695217

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  68 in total

Review 1.  Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs.

Authors:  Xiangyi Lu; Li Xiao; Luan Wang; Douglas M Ruden
Journal:  Biochem Pharmacol       Date:  2011-11-22       Impact factor: 5.858

2.  Heat shock protein 90α (Hsp90α) is phosphorylated in response to DNA damage and accumulates in repair foci.

Authors:  Maria Quanz; Aurélie Herbette; Mano Sayarath; Leanne de Koning; Thierry Dubois; Jian-Sheng Sun; Marie Dutreix
Journal:  J Biol Chem       Date:  2012-01-23       Impact factor: 5.157

3.  Drug discovery from natural sources.

Authors:  Young-Won Chin; Marcy J Balunas; Hee Byung Chai; A Douglas Kinghorn
Journal:  AAPS J       Date:  2006-04-14       Impact factor: 4.009

4.  Hsp90 Inhibitor Ganetespib Sensitizes Non-Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation.

Authors:  Yifan Wang; Hui Liu; Lixia Diao; Adam Potter; Jianhu Zhang; Yawei Qiao; Jing Wang; David A Proia; Ramesh Tailor; Ritsuko Komaki; Steven H Lin
Journal:  Clin Cancer Res       Date:  2016-06-28       Impact factor: 12.531

5.  Targeting heat shock protein 90 overrides the resistance of lung cancer cells by blocking radiation-induced stabilization of hypoxia-inducible factor-1alpha.

Authors:  Woo-Young Kim; Seung Hyun Oh; Jong-Kyu Woo; Waun Ki Hong; Ho-Young Lee
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

6.  The purine scaffold Hsp90 inhibitor PU-H71 sensitizes cancer cells to heavy ion radiation by inhibiting DNA repair by homologous recombination and non-homologous end joining.

Authors:  Younghyun Lee; Huizi Keiko Li; Aya Masaoka; Shigeaki Sunada; Hirokazu Hirakawa; Akira Fujimori; Jac A Nickoloff; Ryuichi Okayasu
Journal:  Radiother Oncol       Date:  2016-09-22       Impact factor: 6.280

7.  Asymmetric Hsp90 N domain SUMOylation recruits Aha1 and ATP-competitive inhibitors.

Authors:  Mehdi Mollapour; Dimitra Bourboulia; Kristin Beebe; Mark R Woodford; Sigrun Polier; Anthony Hoang; Raju Chelluri; Yu Li; Ailan Guo; Min-Jung Lee; Elham Fotooh-Abadi; Sahar Khan; Thomas Prince; Naoto Miyajima; Soichiro Yoshida; Shinji Tsutsumi; Wanping Xu; Barry Panaretou; William G Stetler-Stevenson; Gennady Bratslavsky; Jane B Trepel; Chrisostomos Prodromou; Len Neckers
Journal:  Mol Cell       Date:  2014-01-23       Impact factor: 17.970

8.  Hsp90 Inhibitors NVP-AUY922 and NVP-BEP800 May Exert a Significant Radiosensitization on Tumor Cells along with a Cell Type-Specific Cytotoxicity.

Authors:  Natalia Niewidok; Linda-Jacqueline Wack; Sarah Schiessl; Lavinia Stingl; Astrid Katzer; Bülent Polat; Vladimir L Sukhorukov; Michael Flentje; Cholpon S Djuzenova
Journal:  Transl Oncol       Date:  2012-10-01       Impact factor: 4.243

9.  Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma.

Authors:  Junichi Okamoto; Iwao Mikami; Yuichi Tominaga; Kristopher M Kuchenbecker; Yu-Ching Lin; Dawn T Bravo; Genevieve Clement; Adam Yagui-Beltran; M Roshni Ray; Kiyoshi Koizumi; Biao He; David M Jablons
Journal:  J Thorac Oncol       Date:  2008-10       Impact factor: 15.609

10.  Oxidative stress plays a critical role in inactivating mutant BRAF by geldanamycin derivatives.

Authors:  Yayoi Fukuyo; Masahiro Inoue; Takuma Nakajima; Ryuji Higashikubo; Nobuko T Horikoshi; Clayton Hunt; Anny Usheva; Michael L Freeman; Nobuo Horikoshi
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.